Effect of Dupilumab on Airway Inflammation in Patients With Persistent Asthma
Open Access
Abstract
Background: Biologics targeting type 2 cytokines can inhibit airway inflammation and improve lung function in moderate‐to‐severe asthma; however, their impact on airway mucosal inflammatory cells is unclear. This study assessed the effects of dupilumab on airway mucosal and systemic inflammation, and related gene expression in patients with persistent asthma. Methods: In the phase 2a EXPEDITION study (NCT02573233), patients aged 18–65 years were randomised to add‐on dupilumab 300 mg ( n = 20) or placebo ( n = 22) every 2 weeks for 12 weeks. Pre‐ and post‐treatment bronchial biopsies, bronchial brushings, bronchoalveolar lavage (BAL) fluid and blood samples were collected. Clinical and patient‐reported outcomes, gene expression, type 2 biomarkers and safety outcomes were assessed. Results: Dupilumab versus placebo improved lung function and asthma control. No significant changes in eosinophils, mast cells or type 2 helper cells were observed in bronchial biopsies. Downregulation of M2 macrophage‐ and eosinophil ‐associated gene sets was observed in BAL and brushing samples after dupilumab. Dupilumab decreased multiple circulating type 2 biomarkers in peripheral blood ( p unadj < 0.001, p adj < 0.01), goblet cell numbers ( p unadj = 0.0336; p adj = 0.2554) and mucus area ( p unadj = 0.0426; p adj = 0.2554) in bronchial biopsies versus placebo. The safety profile was consistent with the known safety profile of dupilumab. Conclusion: Dupilumab improved lung function and asthma control while reducing circulating type 2 biomarkers. No measurable impact was observed on type 2‐associated inflammatory cell numbers in airway bronchial biopsies; however, dupilumab modulated the expression of inflammation‐associated gene sets. These findings provide cellular and molecular data that may explain dupilumab‐driven mechanisms of improved lung function in patients with type 2 asthma.Keywords
Funding Information
- Regeneron Pharmaceuticals
This publication has 26 references indexed in Scilit:
- Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trialThe Lancet Respiratory Medicine, 2025
- Asthma from immune pathogenesis to precision medicineSeminars in Immunology, 2019
- The Cytokines of AsthmaImmunity, 2019
- Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitisJournal of Allergy and Clinical Immunology, 2019
- Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Respiratory Medicine, 2018
- AsthmaThe Lancet, 2018
- Serum periostin is associated with type 2 immunity in severe asthmaJournal of Allergy and Clinical Immunology, 2016
- IL-4 and IL-13 signaling in allergic airway diseaseCytokine, 2015
- The monocyte‐derived chemokine is released in the bronchoalveolar lavage fluid of steady‐state asthmaticsAllergy, 2003
- ANALYSIS OF NOVEL DISEASE-RELATED GENES IN BRONCHIAL ASTHMACytokine, 2002